The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

Over the last 7 days, the United States market has dropped 1.6%, yet it remains up by an impressive 30% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

Granted, Ocrevus Zunovo is a very large volume subcutaneous version of the drug that requires 10 minutes to administer, and the whole process takes about 55 minutes after the first dose ...

Circle to Search is coming to compatible phones with OxygenOS 15 The update also adds new boot animation, icons, and shelf card choices OxygenOS 15 introduces Gemini-powered AI Notes ...

Roche is looking to use Dyno’s technologies to target neurological diseases, a big focus at the Swiss pharma, with multiple sclerosis blockbuster Ocrevus serving as its best-selling asset.

The FDA also approved Ocrevus Zunovo as the first and only twice-a-year 10-minute subcutaneous injection for patients with relapsing and progressive multiple sclerosis. The European Commission ...

Dubbed Ocrevus Zunovo, the under-the-skin version of the blockbuster CD20 antibody drug could represent an additional CHF 2 billion sales opportunity, Graham said during the investor call.

Vabysmo (eye diseases) was the biggest growth driver of sales, with Phesgo (breast cancer), Ocrevus (multiple sclerosis), Hemlibra (hemophilia) and Polivy (blood cancer) being the other ...